225 related articles for article (PubMed ID: 24023515)
1. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
2. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma.
Gao J; Yu Y; Zhang Y; Song J; Chen H; Li W; Qian W; Deng L; Kou G; Chen J; Guo Y
Biomaterials; 2012 Jan; 33(1):270-82. PubMed ID: 21963149
[TBL] [Abstract][Full Text] [Related]
3. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes.
Gao J; Liu W; Xia Y; Li W; Sun J; Chen H; Li B; Zhang D; Qian W; Meng Y; Deng L; Wang H; Chen J; Guo Y
Biomaterials; 2011 May; 32(13):3459-70. PubMed ID: 21296406
[TBL] [Abstract][Full Text] [Related]
4. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
[TBL] [Abstract][Full Text] [Related]
6. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
7. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.
Wilbur DS; Chyan MK; Hamlin DK; Nguyen H; Vessella RL
Bioconjug Chem; 2011 Jun; 22(6):1089-102. PubMed ID: 21513347
[TBL] [Abstract][Full Text] [Related]
8. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing.
Gao J; Sun J; Li H; Liu W; Zhang Y; Li B; Qian W; Wang H; Chen J; Guo Y
Biomaterials; 2010 Mar; 31(9):2655-64. PubMed ID: 20035999
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes).
Jin S; Li H; Xu Y
Methods Mol Biol; 2023; 2622():197-205. PubMed ID: 36781762
[TBL] [Abstract][Full Text] [Related]
10. PEG-immunoliposome.
Maruyama K
Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
[TBL] [Abstract][Full Text] [Related]
11. Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab'-Immunoliposomes for Gene Silencing in Breast Cancer Cells.
Khan A; Aljarbou AN; Aldebasi YH; Allemailem KS; Alsahli MA; Khan S; Alruwetei AM; Khan MA
Int J Nanomedicine; 2020; 15():5575-5589. PubMed ID: 32801705
[TBL] [Abstract][Full Text] [Related]
12. In vivo targeting by liposomes.
Maruyama K
Biol Pharm Bull; 2000 Jul; 23(7):791-9. PubMed ID: 10919354
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y
Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771
[TBL] [Abstract][Full Text] [Related]
14. Tuned Density of Anti-Tissue Factor Antibody Fragment onto siRNA-Loaded Polyion Complex Micelles for Optimizing Targetability into Pancreatic Cancer Cells.
Min HS; Kim HJ; Ahn J; Naito M; Hayashi K; Toh K; Kim BS; Matsumura Y; Kwon IC; Miyata K; Kataoka K
Biomacromolecules; 2018 Jun; 19(6):2320-2329. PubMed ID: 29767505
[TBL] [Abstract][Full Text] [Related]
15. Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells.
Merdan T; Callahan J; Petersen H; Kunath K; Bakowsky U; Kopecková P; Kissel T; Kopecek J
Bioconjug Chem; 2003; 14(5):989-96. PubMed ID: 13129403
[TBL] [Abstract][Full Text] [Related]
16. Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes.
Kim KS; Lee YK; Kim JS; Koo KH; Hong HJ; Park YS
Cancer Gene Ther; 2008 May; 15(5):331-40. PubMed ID: 18309354
[TBL] [Abstract][Full Text] [Related]
17. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis.
Zhou Z; Zhang J; Zhang Y; Ma G; Su Z
Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095
[TBL] [Abstract][Full Text] [Related]
18. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo.
Maruyama K; Takahashi N; Tagawa T; Nagaike K; Iwatsuru M
FEBS Lett; 1997 Aug; 413(1):177-80. PubMed ID: 9287139
[TBL] [Abstract][Full Text] [Related]
19. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells.
Li T; Amari T; Semba K; Yamamoto T; Takeoka S
Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
